Sandoz hitches its wagon to biosimilars, predicting $3B in sales from pipeline products over next 5 years

Novartis’ generics and biosimilars unit Sandoz—soon to be spun off as a stand-alone company—has seen a decline in revenue every year since 2016. 

But the slide could end soon as the company projects sales of its pipeline products to add $3 billion to the top line over the next five years, thanks largely to its emphasis on biosimilars.